摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-甲氧基-3-(3-甲氧基丙氧基)苯甲酸 | 895240-50-3

中文名称
4-甲氧基-3-(3-甲氧基丙氧基)苯甲酸
中文别名
——
英文名称
4-methoxy-3-(3-methoxy-propoxy)benzoic acid
英文别名
3-(3-methoxy-propoxy)-4-methoxy-benzoic acid;4-methoxy-3-(3-methoxy-propoxy)-benzoic acid;4-Methoxy-3-(3-methoxypropoxy)benzoic acid
4-甲氧基-3-(3-甲氧基丙氧基)苯甲酸化学式
CAS
895240-50-3
化学式
C12H16O5
mdl
——
分子量
240.256
InChiKey
BSMIUCOCVISYDX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.167

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    65
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:fc86f1473332c866a22fedbc9115bba9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
    申请人:Maillard Michel
    公开号:US20060089355A1
    公开(公告)日:2006-04-27
    Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting de-position of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , and X 2 are defined herein.
    本发明涉及使用式(I)中的化合物治疗阿尔茨海默病和其他疾病,抑制β-秘鲁酶的活性,抑制Aβ肽在哺乳动物体内的沉积。其中,变量R1、R2、R3、R4、R5、X1和X2的定义如下。
  • Organic Compounds
    申请人:Ehrhardt Claus
    公开号:US20080194549A1
    公开(公告)日:2008-08-14
    The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.
    本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物制备治疗依赖于肾素活性的疾病的药物制剂;使用该类化合物治疗依赖于肾素活性的疾病;该取代吡咯烷化合物亚类的化合物用于温血动物的诊断和治疗,特别是用于治疗依赖于肾素活性的疾病;该取代吡咯烷化合物亚类的新化合物;包括所述取代吡咯烷化合物的药物制剂和/或包括给予所述取代吡咯烷化合物的治疗方法,特别是制备该新取代吡咯烷化合物的方法,以及其合成的新中间体、起始材料和/或部分步骤。
  • AMIDE DERIVATIVE
    申请人:Nakahira Hiroyuki
    公开号:US20100056497A1
    公开(公告)日:2010-03-04
    The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. wherein R 1a is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; R 1b is an optionally substituted C 1-6 alkoxy, etc.; R 1c is a hydrogen atom, an optionally substituted C 1-6 alkoxy, etc.; R 2 is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3c and R 3d are independently the same or different, and each is a group of the formula: -A-B (in which A is a single bond, —(CH 2 ) s O—, —(CH 2 ) s N(R 4 )CO—, etc., B is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.), etc.; R 4 is a hydrogen atom, an optionally substituted C 1-6 alkyl, etc.; s is 0, etc.; and n is 1, etc.
    本发明涉及一种具有式(I)的化合物,其可用作肾素抑制剂,或其药学上可接受的盐。其中,R1a是氢原子,可选地取代的C1-6烷基等;R1b是可选地取代的C1-6烷氧基等;R1c是氢原子,可选地取代的C1-6烷氧基等;R2是氢原子,可选地取代的C1-6烷基等;R3a,R3b,R3c和R3d独立且相同或不同,每个是式:-A-B的基团(其中A是单键,-(CH2)sO-,-(CH2)sN(R4)CO-等,B是氢原子,可选地取代的C1-6烷基等)等;R4是氢原子,可选地取代的C1-6烷基等;s为0等;n为1等。
  • PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN
    申请人:Breitenstein Werner
    公开号:US20100087427A1
    公开(公告)日:2010-04-08
    Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.
    小说3-单一、3,4-二和3,4,4-三取代吡咯烷化合物,这些化合物用于诊断和治疗温血动物,特别是用于治疗依赖于肾素不适当活性的疾病(=失调);该类化合物用于制备用于治疗依赖于肾素不适当活性的疾病的制药配方;该类化合物用于治疗依赖于肾素不适当活性的疾病;包括所述取代吡咯烷化合物的制药配方和/或包括给予所述取代吡咯烷化合物的治疗方法,以及描述了制备所述取代吡咯烷化合物的新型中间体和部分步骤。所述取代吡咯烷化合物特别是公式I的取代基如说明书所述。
  • Organic compounds
    申请人:Novartis AG
    公开号:US07807709B2
    公开(公告)日:2010-10-05
    The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.
    本发明涉及使用(3,4-二-, 3,3,4-三-, 3,4,4-三-或3,3,4,4-四-)取代吡咯烷化合物来制备用于治疗依赖于肾素活性的疾病的药物制剂;该类化合物在治疗依赖于肾素活性的疾病中的使用;属于这些取代吡咯烷化合物亚类的化合物用于诊断和治疗温血动物,特别是用于治疗依赖于肾素活性的疾病(=失调);属于这些取代吡咯烷化合物亚类的新化合物;包含所述取代吡咯烷化合物的药物制剂,和/或包括给予所述取代吡咯烷化合物的治疗方法,一种用于特别制备这些新的取代吡咯烷化合物的方法,以及其合成的新中间体,起始材料和/或部分步骤。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐